图书简介
This book provides essential information on recent advances in molecular genetics, epidemiology, translational research, and the latest results of clinical trials on mesothelioma. Significant progress has been made in understanding mesothelioma biology, and in developing new therapies for this refractory tumor, malignant pleural mesothelioma (MPM). Not only does this volume summarize the latest research-based data on the disease; it also shares insights into future research directions.The book consists of 5 themed sections on: epidemiology, pathogenesis, screening and early detection, molecular genetics, and clinical aspects and management. Several chapters focus on new trends in the field, e.g. immune therapy and identification of biomarkers, molecular oncogenesis including genetic susceptibility, and molecular diagnostic pathology. The book also highlights new cancer treatment approaches, such as immunotherapy based on immune checkpoint inhibitors, which has meant a paradigm shift in other types of cancer, and given some hope to MPM patients. In turn, it discusses recent molecular pathological studies on mesothelioma, which claim to offer more accurate classifications than traditional morphology and immunohistochemistry-based approaches. All of these cutting-edge analyses provide the basis for a closing discussion on future developments and research directions.Malignant Pleural Mesothelioma - Advances in Pathogenesis, Diagnosis, and Treatments has been edited and authored by respected researchers and will be of interest to medical, surgical and radiation oncologists; pulmonologists; pathologists and basic researchers alike. Since the disease represents a significant diagnostic and therapeutic challenge, scientists and clinicians from learners to experts, as well as fellows in training in these subspecialties, will value this book.
Part I Epidemiology.-1. Recent Trends in the Global Incidence of Mesothelioma: What is the Relationship with an Asbestos Ban?.-Part II Pathogenesis.-2. Asbestos and mesothelioma: What is recent advance in research on asbestos-induced molecular carcinogenesis?.-3. Asbestos fiber and immunological effects: Do immunological effects play any role in asbestos-related diseases?.-4. Biomolecular pathways in mesothelioma: What is new perspective on biomolecular research for mesothelioma?.-Part IIIScreening and early detection.-5. Biomarkers for mesothelioma screening: How can we identify subjects developing mesothelioma in asbestos-exposed high-risk group?.-6. Pleural Plaques as a predictive imaging marker for cancer screening in asbestos-exposed subjects: Can pleural plaques be a tool beyond estimating past asbestos inhalation?.-Part IV Pathology.-7. Anatomical structure of the pleura and mesothelial cells: What are the characteristic features?.-8. Histologic classification of tumors of the pleura: Advances after WHO 2015 classification.-9. Pathology of mesothelioma, subtypes and rare variants: What is the role of immunohistochemical markers in differential diagnosis?.-10. Cytopathologic diagnosis of mesothelioma: Can we diagnose mesothelioma based on fluid cytological materials without biopsy?.-11. Circulating tumor cells in malignant pleural mesothelioma: What is the role of liquid biopsy in clinical practice of malignant pleural mesothelioma?.-Part V Molecular Genetics.-12. Recent advances on the pathogenesis of mesothelioma in genetics and genomics: What are novel insights into mesothelioma biology?.-13. Genetic predisposition to mesothelioma: What are the biological mechanisms and what are the clinical characteristics of these mesotheliomas?.-14. Frequent NF2 inactivation in mesothelioma: How can we treat mesothelioma with targeted therapies for molecular aberrations?.-Part VI Clinical Features and Management.-15. Use of Tunneled Catheters versus Pleurodesis for Mesothelioma: When should we use one or the other, or both?.-16. Advanced minimally invasive approach with medical thoracoscopy for mesothelioma: What are the roles in diagnosis?.-17. Imaging evaluation of local tumor growth in malignant pleural mesothelioma: What is the role of imaging modalities in curative intent surgery for mesothelioma?.-18. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma: What is the role in mesothelioma detection and treatment response assessment?.-19. Palliation in malignant pleural mesothelioma: How to manage clinical symptoms in mesothelioma.-20. Supportive care for advanced mesothelioma: What is the role of mesothelioma nurses in clinical practice?.-Part VII Treatment; Current standard and future perspective.-21. Antiangiogenic therapies for mesothelioma: What is the role in mesothelioma treatment?.-22. Systemic chemotherapy for unresectable pleural mesothelioma from frontline to salvage treatment : How can we treat the patients failed to PD-1/PD-L1 inhibitors?.-23. Biomarkers for Immune checkpoint inhibitors in mesothelioma: What are the roles of biomarkers for optimal immune therapy?.-24. Promising investigational new drugs for mesothelioma: What is the next stage of the treatment for advanced mesothelioma?.-25. Viral immune therapy and other virotherapies for advanced mesothelioma: Are we ready for clinical trials of viral immune therapy?.-Part VIII Radiotherapy.-26. Impact of Radiation Therapy on Malignant Mesothelioma: Are we ready for use in clinical practice, combined with surgery or alone?.-Part IX. Surgical Intervention; Current status and future perspectives.-27. TNM classification and the role of curative intent surgery for mesothelioma: Is the debate on extra-pleural pneumonectomy versus lung-sparing macroscopic resection over?.-28. Surgery and adjuvant or neoadjuvant setting of radiotherapy: What is the role of radiotherapy in combination with lung-sparing surgery?.-29. Loco-regional treatment with surgical intervention in mesothelioma: What is the role of enhancing local control approaches?.
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐